Oligonucleotides are poised for high growth over the next five years, with the market doubling in value during this time frame. This growth is driven by the high application potential of oligonucleotides to be used in the treatments of a variety of medical conditions, the growing number of FDA approved oligonucleotide drugs, an increased focus on customized or personalized medicine, and a continued emphasis on the development of therapeutics for rare disease.
As a result, contract development and manufacturing organizations (CDMOs), such as Ajinomoto Bio-Pharma Services, are seeing increased demand for oligonucleotide synthesis. However, with this developing market comes some considerable challenges for drug manufacturers in the ability to cost-effectively, quickly and easily scale from research amounts to commercial needs.
In this white paper, we will discuss how Ajinomoto Bio-Pharma Services meets this seamless supply challenge by providing development, scale-up and synthesis capabilities of research to commercial quantities of customized oligonucleotides.